Mumbai (Maharashtra) [India], February 11 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food and Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1 per cent, the generic version of Cleocin T® Gel, 1 per cent, of Pharmacia and Upjohn.
niravFebruary 11, 2021 15
The New Report “Coronavirus Treatment Drugs Market” published by Coherent Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The research dives deep into the global share, size, and trends, as well as the growth rate of the
Coronavirus Treatment Drugs Market to project its progress during the forecast period. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Coronavirus Treatment Drugs market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to
niravFebruary 11, 2021 27
The New Report “Mental Disorder Treatment Market” published by Coherent Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The research dives deep into the global share, size, and trends, as well as the growth rate of the
Mental Disorder Treatment Market to project its progress during the forecast period. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Mental Disorder Treatment market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to
PTI | New Delhi | Updated: 09-02-2021 22:01 IST | Created: 09-02-2021 22:01 IST
Glenmark Pharmaceuticals on Tuesday said its board will meet later this week to consider buyback of its Singapore-listed foreign currency convertible bonds (FCCBs). .a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited will be held on February 12, 2021, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its USD 200 million (as on date outstanding USD 113.5 million) 2 per cent resettable onward starting equity-linked securities due June 28, 2022, issued in 2016 ( FCCBonds )., the company said in a regulatory filing.
The operations committee, based on market opportunities and conditions, will hold meetings to consider and approve the terms and conditions of any tenders or buybacks, it added.